elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause
Elinzanetant is an antagonist of neurokinin (NK)-1 and NK-3 receptors.
Mechanism of action:
- hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons express several receptor/ligand pairs, including neurokinin (NK)–1 and NK-3 receptors and their respective ligands, substance P (SP) and neurokinin B (NKB)
- during and after the menopausal transition, declining estrogen levels lead to hypertrophy and hyperactivity of KNDy neurons, which is accompanied by an overexpression of neurotransmitters, including NKB and SP
- this hyperactivation has been shown to be concurrent with thermoregulatory disruption that results in VMS (vasomotor symptoms)
- SP and NK-1 receptors may also have a role in peripheral vasodilatation and primary insomnia
- elinzanetant is a non-hormonal selective antagonist of NK1 and NK3 receptors (2)
A review notes (2)
- in two clinical trials, elinzanetant modestly reduced VMS frequency and severity more than placebo at 12 weeks
- in indirect comparisons, HRT is the most effective treatment for reducing the frequency of VMS symptoms, while NK3 antagonists show modest efficacy
Reference:
- Panay N et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA Intern Med. 2025 Nov 1;185(11):1319-1327.
- Elinzanetant for menopause.Drug and Therapeutics Bulletin Published Online First: 26 November 2025.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.